Fulcrum Therapeutics Stock Performance

FULC Stock  USD 10.87  0.53  5.13%   
On a scale of 0 to 100, Fulcrum Therapeutics holds a performance score of 6. The firm shows a Beta (market volatility) of -1.42, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Fulcrum Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Fulcrum Therapeutics is expected to outperform it. Please check Fulcrum Therapeutics' jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to make a quick decision on whether Fulcrum Therapeutics' price patterns will revert.

Risk-Adjusted Performance

Mild

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Fulcrum Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather conflicting essential indicators, Fulcrum Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
5.13
Five Day Return
11.95
Year To Date Return
(0.46)
Ten Year Return
(19.48)
All Time Return
(19.48)
1
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
12/05/2025
2
Disposition of 3452 shares by Oltmans Curtis Gale of Fulcrum Therapeutics at 12.92 subject to Rule 16b-3
12/15/2025
3
Wall Street Analysts Think Fulcrum Therapeutics Could Surge 58.47 percent Read This Before Placing a Bet
12/30/2025
4
Disposition of 15000 shares by Gould Robert J of Fulcrum Therapeutics at 11.8726 subject to Rule 16b-3
01/02/2026
5
Fulcrum Therapeutics, Inc. Stock Analysis A Biotech With A 90 percent Upside Potential - DirectorsTalk Interviews
01/08/2026
6
Can Fulcrum Therapeutics Inc. disrupt its industry - Weekly Trading Summary Free Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com
01/14/2026
7
Acquisition by Tourangeau Greg of 6500 shares of Fulcrum Therapeutics subject to Rule 16b-3
01/21/2026
8
Acquisition by Sapir Alex of 650000 shares of Fulcrum Therapeutics at 10.72 subject to Rule 16b-3
02/02/2026
Begin Period Cash Flow26.7 M
Total Cashflows From Investing Activities32.2 M

Fulcrum Therapeutics Relative Risk vs. Return Landscape

If you would invest  865.00  in Fulcrum Therapeutics on November 14, 2025 and sell it today you would earn a total of  222.00  from holding Fulcrum Therapeutics or generate 25.66% return on investment over 90 days. Fulcrum Therapeutics is currently generating 0.6379% in daily expected returns and assumes 7.7912% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of stocks are less volatile than Fulcrum, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Fulcrum Therapeutics is expected to generate 10.09 times more return on investment than the market. However, the company is 10.09 times more volatile than its market benchmark. It trades about 0.08 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.14 per unit of risk.

Fulcrum Therapeutics Target Price Odds to finish over Current Price

The tendency of Fulcrum Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 10.87 90 days 10.87 
about 44.55
Based on a normal probability distribution, the odds of Fulcrum Therapeutics to move above the current price in 90 days from now is about 44.55 (This Fulcrum Therapeutics probability density function shows the probability of Fulcrum Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Fulcrum Therapeutics has a beta of -1.42. This usually indicates as returns on its benchmark rise, returns on holding Fulcrum Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Fulcrum Therapeutics is expected to outperform its benchmark. Additionally Fulcrum Therapeutics has an alpha of 0.8943, implying that it can generate a 0.89 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Fulcrum Therapeutics Price Density   
       Price  

Predictive Modules for Fulcrum Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Fulcrum Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
3.1610.9518.74
Details
Intrinsic
Valuation
LowRealHigh
4.7912.5820.37
Details
7 Analysts
Consensus
LowTargetHigh
17.3819.1021.20
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.38-0.3-0.21
Details

Fulcrum Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Fulcrum Therapeutics is not an exception. The market had few large corrections towards the Fulcrum Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Fulcrum Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Fulcrum Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.89
β
Beta against Dow Jones-1.42
σ
Overall volatility
1.46
Ir
Information ratio 0.09

Fulcrum Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Fulcrum Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Fulcrum Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Fulcrum Therapeutics is way too risky over 90 days horizon
Fulcrum Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 80 M. Net Loss for the year was (9.72 M) with loss before overhead, payroll, taxes, and interest of (52.4 M).
Fulcrum Therapeutics currently holds about 221.79 M in cash with (2.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26.
Over 81.0% of the company shares are owned by institutional investors
Latest headline from globenewswire.com: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635

Fulcrum Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Fulcrum Stock often depends not only on the future outlook of the current and potential Fulcrum Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Fulcrum Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding62 M
Cash And Short Term Investments241 M

Fulcrum Therapeutics Fundamentals Growth

Fulcrum Stock prices reflect investors' perceptions of the future prospects and financial health of Fulcrum Therapeutics, and Fulcrum Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fulcrum Stock performance.

About Fulcrum Therapeutics Performance

By analyzing Fulcrum Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Fulcrum Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Fulcrum Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Fulcrum Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand(2.85)(2.71)
Return On Tangible Assets(0.03)(0.04)
Return On Capital Employed(0.08)(0.08)
Return On Assets(0.03)(0.04)
Return On Equity(0.04)(0.04)

Things to note about Fulcrum Therapeutics performance evaluation

Checking the ongoing alerts about Fulcrum Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fulcrum Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Fulcrum Therapeutics is way too risky over 90 days horizon
Fulcrum Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 80 M. Net Loss for the year was (9.72 M) with loss before overhead, payroll, taxes, and interest of (52.4 M).
Fulcrum Therapeutics currently holds about 221.79 M in cash with (2.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26.
Over 81.0% of the company shares are owned by institutional investors
Latest headline from globenewswire.com: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Evaluating Fulcrum Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Fulcrum Therapeutics' stock performance include:
  • Analyzing Fulcrum Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fulcrum Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Fulcrum Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Fulcrum Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fulcrum Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Fulcrum Therapeutics' stock. These opinions can provide insight into Fulcrum Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Fulcrum Therapeutics' stock performance is not an exact science, and many factors can impact Fulcrum Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Fulcrum Stock analysis

When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Global Correlations
Find global opportunities by holding instruments from different markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Fundamental Analysis
View fundamental data based on most recent published financial statements
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing